CalRx Biosimilar Insulin: California's Initiative to Enter the Insulin Market

被引：2
|
作者：
Feldman, Robin [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Coll Law San Francisco, San Francisco, CA USA
[2] Univ Calif San Francisco, Coll Law San Francisco, 200 McAllister St, San Francisco, CA 94102 USA
来源：
JAMA INTERNAL MEDICINE | 2023年 / 183卷 / 10期
关键词：
D O I：
10.1001/jamainternmed.2023.3280
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This viewpoint evaluates California's CalRx Biosimilar Insulin Initiative, which aims to address insulin affordability by offering less expensive alternatives to existing products, specifically targeting patients with insulin-dependent diabetes.
引用
收藏
页码：1043 / 1044
页数：2
相关论文
共 50 条
  • [21] Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine
    Kumar, K. M. Prasanna
    Chowdhury, Subhankar
    Bantwal, Ganapathi
    Unnikrishnan, A. G.
    Kalra, Sanjay
    Aggarwal, Sameer
    Singh, Awadhesh Kumar
    Pandit, Kaushik
    Shukla, Rishi
    Vishwanathan, Vijay
    Khobragade, Kunal
    Sarda, Prashant S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [22] Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
    Home, Philip
    Derwahl, Karl-Michael
    Ziemen, Monika
    Wernicke-Panten, Karin
    Pierre, Suzanne
    Kirchhein, Yvonne
    Garg, Satish K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (02) : 160 - 170
  • [23] The Emergence of Biosimilar Insulin Preparations-A Cause for Concern?
    Owens, David R.
    Landgraf, Wolfgang
    Schmidt, Andrea
    Bretzel, Reinhard G.
    Kuhlmann, Martin K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (11) : 989 - 996
  • [24] Erstes Insulin-Biosimilar in Deutschland verfügbar
    MMW - Fortschritte der Medizin, 2015, 157 (16) : 68 - 68
  • [25] The role of biosimilar manufacturers in improving access to insulin globally
    Perrin, Christophe
    Ewen, Margaret
    Beran, David
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 578 - 578
  • [26] Evaluation of biosimilar insulin use: Perception and experience (INSPIRE)
    Donnelly, R.
    Burke, M.
    Haire, L.
    Baxter, S.
    Munday, W.
    DIABETIC MEDICINE, 2018, 35 : 157 - 157
  • [27] In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps
    Mohnicke, Mandy
    Blecher, Arnd
    Beichert, Kathrin
    Bidlingmaier, Bernd
    Todt, Ernst -Josef
    Dette, Christoph
    Rotthaeuser, Baerbel
    Mukherjee, Bhaswati
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (04) : 963 - 973
  • [28] BIOT 173-Manufacture of biosimilar insulin and GCSF
    Iyer, Harish
    Akundi, Sriram
    Chandavarkar, Arun
    Suryanarayan, Shrikumar
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [29] Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
    White, John
    Goldman, Jennifer
    JOURNAL OF PHARMACY TECHNOLOGY, 2019, 35 (01) : 25 - 35
  • [30] State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar
    Kwon, Youngmin
    Sarpatwari, Ameet
    Dusetzina, Stacie B.
    JAMA HEALTH FORUM, 2025, 6 (04):
12345